Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Dendreon up on request for Provenge hearing

DNDN gained $1.34 (24%) to $6.98 on Thursday after Reps. Mike Michaud (D-Maine), Dan Burton (R-Ind.) and Tim Ryan (D-Ohio) sent a letter to the House

Read the full 262 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE